DPH Commissioner Robbie Goldstein says the CDC is spreading vaccine misinformation that is "deeply troubling and even dangerous."

Hayden S Andrews, M.D, Meena Murthy, C.N.P, Benjamin T Davis, M.D; Anal cancer screening: a balanced approach is necessary, Clinical Infectious Diseases, ,

HIV-1 persists lifelong despite effective antiretroviral therapy, yet the mechanisms underlying this persistence remain incompletely understood. Recent work by Wei et al. and Gao et al. reveals that t...

Author summary The microorganisms that live in and on our bodies—collectively known as the microbiome—can influence our health in many ways, including how our immune system behaves and how susceptible...

The HIV epidemic remains a critical public health challenge in the Southern U.S., where barriers such as healthcare shortages, structural racism, and social determinants of health exacerbate dispariti...

AbstractBackground. There is a need to build public support for the conduct of HIV cure research. It is important to enhance the public understanding of HI

Click on the article title to read more.

IntroductionIt has previously been established that there is an increased incidence of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene amongst patients with non-cystic fibrosis bronchiectasis (NCFB). With the advent of new highly effective CFTR modulators, specifically elexacaftor–tezacaftor–ivacaftor (ETI), we asked whether NCFB patients with a single ETI amenable mutation who do not meet the criteria for a diagnosis of cystic fibrosis (CF) would benefit from this therapy.MethodsWe assembled a retrospective cohort of patients (n=12) with a single CFTR mutation amenable to ETI treatment. Patients included in this cohort did not meet the diagnostic criteria for CF but presented with similar pulmonary symptoms and frequent exacerbations. Medical records were reviewed to determine the effects of ETI on clinical outcomes. Paired sample t-test for univariate analysis and multivariate linear mixed effect modeling for continuous and categorical variables were used to examine the impact of ETI therapy.ResultsImprovements in pulmonary symptoms were observed in all 12 patients (100%), and 11 patients (91.6%) expressed improvement in quality of life. Mean % predicted forced expiratory volume in 1 s improved significantly from 69.3% to 75.0% (p=0.007). Mean reported pulmonary symptoms decreased to 2.17 (p=0.007) and mean reported pulmonary exacerbations decreased to 1.08 per year (p=0.0006). When controlling for sweat chloride and Poly T insertions, post-ETI improvement remained significant.ConclusionAmongst patients presenting with NCFB and an amenable CFTR mutation, treatment with ETI improved lung function, symptoms and quality of life and led to a significant reduction in annual pulmonary exacerbations. Larger clinical studies are needed to further validate these findings.

Recent United States (US) immigration policies have left thousands of asylum seekers stranded in Mexican border cities with limited access to healthca…

Improving perinatal engagement in HIV care is critical to prevent disease progression and transmission. In Haiti and other low-resource settings, poverty contributes substantially to poor perinatal HI...

Objective The aging population of people with HIV (PWH) raises heightened concerns regarding accelerated aging and dementia. Portable, low-field MRI (LF-MRI) is an innovative technology that could e...

The purpose of this study was to understand the impact of the coronavirus disease 2019 (COVID-19) pandemic and mitigation efforts on health and social outcomes for people with HIV at the individual, s...

Background: What You Need to Know

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunizati...

The Citrobacter rodentium CRISPR–Cas system is activated by the oxygen-responsive transcriptional regulator Fnr in the anoxic environment of the mouse gut.